These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 20530493)

  • 1. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis.
    Sreekanthreddy P; Srinivasan H; Kumar DM; Nijaguna MB; Sridevi S; Vrinda M; Arivazhagan A; Balasubramaniam A; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
    Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1409-22. PubMed ID: 20530493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis.
    Reddy SP; Britto R; Vinnakota K; Aparna H; Sreepathi HK; Thota B; Kumari A; Shilpa BM; Vrinda M; Umesh S; Samuel C; Shetty M; Tandon A; Pandey P; Hegde S; Hegde AS; Balasubramaniam A; Chandramouli BA; Santosh V; Kondaiah P; Somasundaram K; Rao MR
    Clin Cancer Res; 2008 May; 14(10):2978-87. PubMed ID: 18483363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis.
    Ljubimova JY; Lakhter AJ; Loksh A; Yong WH; Riedinger MS; Miner JH; Sorokin LM; Ljubimov AV; Black KL
    Cancer Res; 2001 Jul; 61(14):5601-10. PubMed ID: 11454714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization.
    Colin C; Baeza N; Bartoli C; Fina F; Eudes N; Nanni I; Martin PM; Ouafik L; Figarella-Branger D
    Oncogene; 2006 May; 25(19):2818-26. PubMed ID: 16314830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cathepsin D is a potential serum marker for poor prognosis in glioma patients.
    Fukuda ME; Iwadate Y; Machida T; Hiwasa T; Nimura Y; Nagai Y; Takiguchi M; Tanzawa H; Yamaura A; Seki N
    Cancer Res; 2005 Jun; 65(12):5190-4. PubMed ID: 15958563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma.
    Somasundaram K; Reddy SP; Vinnakota K; Britto R; Subbarayan M; Nambiar S; Hebbar A; Samuel C; Shetty M; Sreepathi HK; Santosh V; Hegde AS; Hegde S; Kondaiah P; Rao MR
    Oncogene; 2005 Oct; 24(47):7073-83. PubMed ID: 16103883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme.
    Ruano Y; Mollejo M; Camacho FI; Rodríguez de Lope A; Fiaño C; Ribalta T; Martínez P; Hernández-Moneo JL; Meléndez B
    Cancer; 2008 Apr; 112(7):1575-84. PubMed ID: 18260157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of histological markers for malignant glioma by genome-wide expression analysis: dynein, alpha-PIX and sorcin.
    Yokota T; Kouno J; Adachi K; Takahashi H; Teramoto A; Matsumoto K; Sugisaki Y; Onda M; Tsunoda T
    Acta Neuropathol; 2006 Jan; 111(1):29-38. PubMed ID: 16320026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma.
    Santosh V; Arivazhagan A; Sreekanthreddy P; Srinivasan H; Thota B; Srividya MR; Vrinda M; Sridevi S; Shailaja BC; Samuel C; Prasanna KV; Thennarasu K; Balasubramaniam A; Chandramouli BA; Hegde AS; Somasundaram K; Kondaiah P; Rao MR
    Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1399-408. PubMed ID: 20501753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma-specific protein interaction network identifies PP1A and CSK21 as connecting molecules between cell cycle-associated genes.
    Ladha J; Donakonda S; Agrawal S; Thota B; Srividya MR; Sridevi S; Arivazhagan A; Thennarasu K; Balasubramaniam A; Chandramouli BA; Hegde AS; Kondaiah P; Somasundaram K; Santosh V; Rao SM
    Cancer Res; 2010 Aug; 70(16):6437-47. PubMed ID: 20663907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.
    Kuan CT; Wakiya K; Dowell JM; Herndon JE; Reardon DA; Graner MW; Riggins GJ; Wikstrand CJ; Bigner DD
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1970-82. PubMed ID: 16609006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
    Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
    Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of osteopontin expression in human gastric carcinoma.
    Higashiyama M; Ito T; Tanaka E; Shimada Y
    Ann Surg Oncol; 2007 Dec; 14(12):3419-27. PubMed ID: 17896150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value.
    Reddy PS; Umesh S; Thota B; Tandon A; Pandey P; Hegde AS; Balasubramaniam A; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
    Cancer Biol Ther; 2008 May; 7(5):663-8. PubMed ID: 18728403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables.
    Zhou YH; Hess KR; Liu L; Linskey ME; Yung WK
    Neuro Oncol; 2005 Oct; 7(4):485-94. PubMed ID: 16212813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between laminin-8 and glial tumor grade, recurrence, and patient survival.
    Ljubimova JY; Fugita M; Khazenzon NM; Das A; Pikul BB; Newman D; Sekiguchi K; Sorokin LM; Sasaki T; Black KL
    Cancer; 2004 Aug; 101(3):604-12. PubMed ID: 15274074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the prognostic value of CD44 in glioblastoma multiforme.
    Wei KC; Huang CY; Chen PY; Feng LY; Wu TW; Chen SM; Tsai HC; Lu YJ; Tsang NM; Tseng CK; Pai PC; Shin JW
    Anticancer Res; 2010 Jan; 30(1):253-9. PubMed ID: 20150644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray.
    Yin D; Ogawa S; Kawamata N; Tunici P; Finocchiaro G; Eoli M; Ruckert C; Huynh T; Liu G; Kato M; Sanada M; Jauch A; Dugas M; Black KL; Koeffler HP
    Mol Cancer Res; 2009 May; 7(5):665-77. PubMed ID: 19435819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic identification of haptoglobin α2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth.
    Kumar DM; Thota B; Shinde SV; Prasanna KV; Hegde AS; Arivazhagan A; Chandramouli BA; Santosh V; Somasundaram K
    J Proteome Res; 2010 Nov; 9(11):5557-67. PubMed ID: 20822092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum GFAP is a diagnostic marker for glioblastoma multiforme.
    Jung CS; Foerch C; Schänzer A; Heck A; Plate KH; Seifert V; Steinmetz H; Raabe A; Sitzer M
    Brain; 2007 Dec; 130(Pt 12):3336-41. PubMed ID: 17998256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.